Start free

PolicyChanges tracks payer policy changes for medical practices and tells you what to do before they take effect.

Create a free accountPolicy Monitoring is free. No card required.
← Back to list
Independence Blue CrossMedicare Advantage · Administrative · Medical Policy · NJ · Genetics, Hematology, Pediatrics +1 moreLow impact

MA08.023c, Enzyme Replacement for the Treatment of Gaucher's Disease

Effective date
Not stated in the notice
Identified
Jun 19, 2026

Summary

Independence Blue Cross has reissued Medicare Advantage medical policy MA08.023c for enzyme replacement therapy (ERT) treating Gaucher's disease as part of their annual review process. The policy covers three FDA-approved medications (imiglucerase, taliglucerase alfa, and velaglucerase alfa) for confirmed Type 1 Gaucher's disease or non-neuropathic Type 3 cases when medical necessity criteria and specific dosing requirements are met. No substantive coverage changes are documented in this routine annual reissuance.

Get alerts when payers change rules like this one

We check Independence Blue Cross and other payers every day and email you when a change matches your specialty and state.

Get Independence Blue Cross alertsPolicy Monitoring is free. No card required.

What to do

Action · 5 steps
01No immediate action required.
02This is a routine annual policy review with no substantive coverage changes.
03Billing teams should verify their systems correctly process claims for J1786 (imiglucerase), J3060 (taliglucerase alfa), and J3385 (velaglucerase alfa) when submitted with diagnosis code E75.22 and appropriate medical documentation confirming Gaucher's disease diagnosis and required dosing.
04Ensure prior authorizations (if required by your specific plan) reference this current MA08.023c policy version.
05Note: The policy has been superseded by MA08.023d as of 05/28/2025; confirm your claims are being evaluated against the current version in the IBX portal.

Codes mentioned

J1786J3060J3385E75.22

Original notice

MA08.023c, Enzyme Replacement for the Treatment of Gaucher's Disease
medpolicy.ibx.com · Always check the source before changing claims.
View original ↗

Related changes

See all Independence Blue Cross changes →
MA08.023d, Enzyme Replacement for the Treatment of Gaucher's DiseaseMediumEffective Jan 1, 2026 · Medical Policy08.00.51l, Enzyme Replacement for the Treatment of Gaucher's DiseaseMediumEffective Jan 1, 2024 · Medical Policy08.00.51m, Enzyme Replacement for the Treatment of Gaucher's DiseaseMediumEffective Jan 1, 2026 · Medical PolicyBrowse every Independence Blue Cross change in the policy list

Related policy hubs

Independence Blue Cross policiesNJ policy changesGeneticsHematologyPediatricsInternal MedicineCode J1786Code J3060Code J3385Code E75.22

Summaries are AI-assisted. Always confirm against the original payer notice.

What is PolicyChanges

One workspace for payer rules, prior auth, coding and compliance

Medical practices use PolicyChanges to catch payer changes before they cause denials. Every change is summarized in plain English, with the codes involved, the date it takes effect and what to do.

Policy MonitoringPayer policy, prior auth and coding changes, filtered to your saved searchesOIG ScreeningStaff and vendors screened every month against OIG LEIE, SAM.gov and state Medicaid listsPrior Auth LookupKnow if a service needs prior authorization before you schedule itCredentialing TrackerLicenses, CAQH, Medicare revalidation and payer enrollments, with reminders before anything lapsesCompliance CenterKeep your HIPAA program documented and ready to show
Start freePolicy Monitoring is free. No card required.
Get alerts for changes like thisPolicy Monitoring is free. No card required.Create a free account